Erythropoietin in the treatment of delayed immune hemolysis of a major ABO‐incompatible bone marrow transplant | Zendy

López J. | Zendy; Steegmann J. L. | Zendy; Pérez G. | Zendy; Otero M. J. | Zendy; Berberana M. | Zendy; Cámara R. | Zendy; Lamana M. | Zendy; Villalta M. J. Fernández | Zendy; FernándezRañada J. M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Erythropoietin in the treatment of delayed immune hemolysis of a major ABO‐incompatible bone marrow transplant

Author(s) -

López J.,

Steegmann J. L.,

Pérez G.,

Otero M. J.,

Berberana M.,

Cámara R.,

Lamana M.,

Villalta M. J. Fernández,

FernándezRañada J. M.

Publication year - 1994

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830450308

Subject(s) - hemolysis , abo blood group system , immunosuppression , medicine , immunology , bone marrow , immune system , erythropoietin

Delayed immune hemolysls can be observed after major ABO‐incompatible bone marrow transplants (BMT). The management of these hemolytic eplsodes Includes transfuslofi of group O red blood cells and increases of immunosuppression. Here we report the case of a 25‐year‐old patient who developed overt immune hemolysis on day +50 after a HLA‐identical ABO‐incompatible BMT. To avoid added immunosuppression, erythropoietin was started: an Increase in reticulocytes sufficlent to maintain hemoglobin despite perslstent hemolysis was observed. We conclude that erythropoletin may have a role In the management of delayed‐onset hemolysis of major ABO‐incompatible BMT, especially when added Immunosuppresslon is undesirable. © 1994 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research